FDA Okays First Treatment for Generalized Pustular Psoriasis FDA Okays First Treatment for Generalized Pustular Psoriasis

Spesolimab, a selective monoclonal antibody that blocks interleukin-36 receptors, had received orphan drug and breakthrough therapy designation and underwent priority review.FDA Approvals

Source: Medscape Medical News Headlines - September 2, 2022 Category: Consumer Health News Tags: Dermatology News Alert Source Type: news